

United States Patent [19]

[11] **Patent Number:** **5,599,984**

Bianchi et al.

[45] **Date of Patent:** **Feb. 4, 1997**

- [54] **GUANYLHYDRAZONES AND THEIR USE TO TREAT INFLAMMATORY CONDITIONS**
- [75] Inventors: **Marina Bianchi**, Milan, Italy; **Anthony Cerami**, Shelter Island, N.Y.; **Kevin J. Tracey**, Old Greenwich, Conn.; **Peter Ulrich**, Old Tappan, N.J.
- [73] Assignee: **The Picower Institute For Medical Research**, Manhasset, N.Y.
- [21] Appl. No.: **315,170**
- [22] Filed: **Sep. 29, 1994**

Related U.S. Application Data

- [63] Continuation-in-part of Ser. No. 184,540, Jan. 21, 1994, abandoned.
- [51] **Int. Cl.⁶** **C07C 233/05**
- [52] **U.S. Cl.** **564/157; 564/48; 564/50; 564/51; 564/148; 564/151; 564/155; 564/227; 564/228; 564/236; 564/332**
- [58] **Field of Search** **564/148, 151, 564/155, 157, 236**

References Cited

U.S. PATENT DOCUMENTS

3,799,988 3/1974 Hashimoto et al. 564/151

OTHER PUBLICATIONS

Berger et al., 1991, "Hydroxylation of Pentamidine by Rat Liver Microsomes" *The Journal of Pharmacology and Experimental Therapeutics* 256: 883-889.

Beutler and Cerami, 1988, "The Common Mediator of Shock, Cachexia and Tumor Necrosis", *Advances in Immunology* 42: 213-231.

Billiar et al., 1990, "Modulation of Nitrogen Oxide Synthesis In Vivo: N^G-Monomethyl-L-Arginine Inhibits Endotoxin-Induced Nitrite/Nitrate Biosynthesis While Promoting Hepatic Damage", *Journal of Leukocyte Biology* 48: 565-569.

Bouskela and Rubanyi, 1994, "Effects of N_γ-Nitro-L-Arginine and Dexamethasone on Early Events Following Lipopolysaccharide Injection: Observations in the Hamster Cheek Pouch Microcirculation" *SHOCK* 1: 347-353.

Brennan, M. F., 1981, "Total Parenteral Nutrition in the Cancer Patient", *The New England Journal of Medicine* 305: 375-382.

Cobb et al., 1992, "N^ω-Amino-L-Arginine, an Inhibitor of Nitric Oxide Synthase, Raises Vascular Resistance but Increases Mortality Rates in Awake Canines Challenge with Endotoxin", *J. Exp. Med.* 176: 1175-1182.

Darling et al., 1990, "Cachectic Effects of Recombinant Human Tumor Necrosis Factor in Rats", *Cancer Research* 50: 4008-4013.

Detsky et al., 1987, "Perioperative Parenteral Nutrition: A Meta-Analysis", *Annals of Internal Medicine* 107: 195-203.

Ding et al., 1988, "Release of Reactive Nitrogen Intermediates and Reactive Oxygen Intermediates from Mouse Peritoneal Macrophages", *The Journal of Immunology* 141: 2407-2412.

Granger et al., 1990, "Metabolic Fate of L-Arginine in Relation to Microbiostatic Capabilities of Murine Macrophages", *J. Clin. Invest.* 85: 264-273.

Hibbs et al., 1987, "Macrophage Cytotoxicity: Role for L-Arginine Deiminase and Imino Nitrogen Oxidation to Nitrite", *Science* 235: 473-476.

Kemp and Petrakis, 1981, "Synthesis and Conformational Analysis of *cis,cis*-1,3,5-Trimethylcyclohexane-1,3,5-tricarboxylic Acid", *J. Org. Chem.* 46: 5140-5143.

Kilbourn et al., 1990, "Reversal of Endotoxin-Mediated Shock by N^G-Methyl-L-Arginine, An Inhibitor of Nitric Oxide Synthesis", *Biochemical and Biophysical Research Communications* 172: 1132-1138.

Koretz, R. L., 1984, "Parenteral Nutrition, Is it Oncologically Logical?" *Journal of Clinical Oncology* 2: 534-538.

Korytnyk et al., 1978, "guanylhya zones with Potential Antileukemic Activity. 2. Synthesis and Structure-Activity Relationships of Analogues of 4,4'-Diacetyl-N, N'-diphenylurea Bis(guanylhya zone)^{1,2}", *Journal of Medicinal Chemistry* 21: 507-513.

Kubes et al., 1992, "Participation in α₂-adrenergic receptors in neural vascular tone of canine skeletal muscle", *The American Journal of Physiology* 262: H611-H615

Langstein et al., 1989, "Reversal of Cancer Cachexia by Antibodies to Interferon-Gamma but not Cachectin/Tumor Necrosis Factor", *Surgical Forum* 15: 408-410.

McGeer et al., 1989, "Parenteral Nutrition in Patients Receiving Cancer Chemotherapy", *Annals of Internal Medicine* 110: 734-736.

Minnard et al., 1994, "Inhibition of Nitric Oxide Synthesis Is Detrimental During Endotoxemia", *Arch. Surg.* 129: 142-148.

Nathan, Carl, 1992, "Nitric oxide as a secretory product of mammalian cells", *The FASEB Journal* 6: 3051-3064.

Sherry et al., 1989, "Anticachectin/tumor necrosis factor-α antibodies attenuate development of cachexia in tumor models", *The FASEB Journal* 3: 1956-1962.

Ulrich and Cerami, 1984, "Trypanocidal 1,3-Arylene Diketone Bis(Guanylhya zone)s. Structure-Activity Relationships among Substituted and Heterocyclic Analogues" *Journal of Medicinal Chemistry* 27: 35-40.

(List continued on next page.)

Primary Examiner—Shailendra Kumar
Attorney, Agent, or Firm—Pennie & Edmonds

[57] **ABSTRACT**

This invention concerns new methods and compositions that are useful in preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly, the invention relates to aromatic guanylhya zone (more properly termed amidinohya zone) compositions and their use to inhibit the uptake of arginine by macrophages and/or its conversion to urea. These compositions and methods are also useful in preventing the generation of nitric oxide (NO) by cells, and so to prevent NO-mediated inflammation and other responses in persons in need of same. In another embodiment, the compounds can be used to inhibit arginine uptake in arginine-dependent tumors and infections.